Core Viewpoint - Securities class action lawsuits have been filed against DexCom, Inc. for alleged misleading statements and undisclosed risks related to its G6 and G7 continuous glucose monitoring systems during the specified Class Period from January 8, 2024, to September 17, 2025 [1][2]. Summary by Sections Allegations Against DexCom - Defendants allegedly made false or misleading statements regarding unauthorized design changes to the G6 and G7 systems, which compromised their reliability and posed health risks to users [2]. - The enhancements claimed for the G7 device were reportedly overstated, and the company downplayed the severity of issues related to the G7 devices [2]. - These actions have led to increased regulatory scrutiny and potential legal, reputational, and financial harm for DexCom [2]. Legal Process for Investors - Investors who suffered losses can seek to be appointed as lead plaintiffs by December 26, 2025, or remain absent class members [3]. - The lead plaintiff will represent the interests of all class members and select legal counsel for the case [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering significant amounts for victims of corporate misconduct [4].

Core Viewpoint - Inspire Medical Systems is facing a class action lawsuit due to alleged violations of federal securities laws, including making false statements about the demand and launch of its Inspire V device [6][9]. Group 1: Legal Action and Investigation - Faruqi & Faruqi, LLP is investigating potential claims against Inspire Medical Systems and has set a deadline of January 5, 2026, for investors to seek the role of lead plaintiff in the class action lawsuit [3]. - Investors who suffered losses between August 6, 2024, and August 4, 2025, are encouraged to contact the law firm to discuss their legal rights [2][3]. Group 2: Company Performance and Issues - On August 4, 2025, Inspire Medical announced significant setbacks in the launch of its Inspire V device, citing delays in training and onboarding at treatment centers [7]. - The company faced billing and reimbursement challenges, as necessary software updates for claims processing were not implemented until July 1, 2025, preventing centers from billing for procedures [8]. - Inspire Medical reported weak demand and excess inventory for the Inspire V device, leading to a more than 80% cut in its 2025 earnings guidance [9]. - Following these announcements, Inspire's stock price plummeted over 32% in one day, resulting in a loss of approximately $1.2 billion in market capitalization [9].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit for securities fraud following a significant stock drop attributed to alleged violations of federal securities laws [1][3]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, while in reality, the company failed to prepare clinicians and payors adequately, leading to delays in adoption and weak demand due to excess inventory of older devices [5][6]. - On August 4, 2025, Inspire disclosed that the launch of Inspire V would take longer than expected, resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. Stock Performance - Following the announcement of the delayed launch, Inspire's stock price fell by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Tandem Diabetes Care securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the misleading information [2]. Group 2: Incident Details - On August 7, 2025, Tandem Diabetes Care announced a voluntary medical device correction for select t:slim X2 insulin pumps due to a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following this announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved notable settlements, including the largest securities class action settlement against a Chinese company and has consistently ranked highly in securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [4].

Core Viewpoint - Rosen Law Firm is encouraging investors of Inspire Medical Systems, Inc. to secure legal counsel before the January 5, 2026 deadline for a class action lawsuit related to the company's stock performance during the specified class period [1][3]. Group 1: Class Action Details - The class period for the Inspire Medical Systems, Inc. stock is from August 6, 2024, to August 4, 2025, inclusive [1]. - Investors who purchased common stock during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and potential lead plaintiffs must act by January 5, 2026 [3]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4]. Group 3: Case Allegations - The lawsuit alleges that Inspire Medical Systems misrepresented key facts about its Inspire V sleep apnea device, including market demand and readiness for launch, leading to misleading statements that inflated investor confidence [5].

Core Insights - Nvidia's stock declined for the second consecutive day despite exceeding earnings estimates, raising concerns about an AI bubble affecting high-flying tech stocks [1][8] - Ross Stores experienced a significant stock surge after surpassing third-quarter sales and profit estimates, indicating strong performance in the back-to-school season and an optimistic outlook for the holiday quarter [2][7] - Oracle's shares fell sharply due to concerns over its elevated valuation and heavy borrowing related to data center investments, marking a 28% decline over the past month [5][7] Company Performance - Nvidia reported third-quarter earnings that surpassed Wall Street expectations, yet its stock fell by 1% as fears of an AI bubble persisted [8] - Ross Stores' shares surged by 8.4% after the company reported strong quarterly results and raised its outlook for the holiday season, reflecting consumer demand for discount retail [2][7] - Insulet's shares rose by 5.8% following an investor day event where the company provided a three-year sales and profit forecast that exceeded expectations [4] Market Reactions - Major U.S. equity indexes rebounded, with the S&P 500 rising by 0.9%, the Dow increasing by 1.1%, and the Nasdaq up by 0.8% [2] - Comments from the Federal Reserve Bank of New York president boosted expectations for potential interest rate cuts, positively impacting stocks in the housing market, including Builders FirstSource, which saw a 7.1% increase [3] - Oracle's stock faced the heaviest decline among S&P 500 stocks, dropping 5.7% amid ongoing valuation concerns [5]

Core Viewpoint - Conavi Medical Corp. has filed a preliminary short form prospectus for an offering of common shares and/or pre-funded common share purchase warrants to support the launch of its Novasight Hybrid system and for general corporate purposes [2][4]. Offering Details - The offering will be conducted on a commercially reasonable efforts agency basis through Bloom Burton Securities Inc. [3] - The final terms, including the number of securities and pricing, will be determined through negotiations between the company and the agent [3]. - The expected closing date for the offering is around December 12, 2025, subject to customary closing conditions and regulatory approvals [5]. Use of Proceeds - The net proceeds from the offering will be utilized to obtain US FDA 510(k) clearance for the Novasight Hybrid system, complete a limited market release, and initiate a broader commercial launch in the United States [4]. Company Overview - Conavi Medical focuses on designing, manufacturing, and marketing imaging technologies for minimally invasive cardiovascular procedures [9]. - The Novasight Hybrid™ System combines intravascular ultrasound (IVUS) and optical coherence tomography (OCT) into a single device, allowing simultaneous imaging of coronary arteries [9][10].

Core Insights - Imperative Care presented positive real-world data on ischemic stroke patients treated with ADAPT 2.0 using the Zoom Stroke System, highlighting excellent reperfusion and rapid procedure times [1][3][4] Group 1: ADAPT 2.0 Overview - ADAPT 2.0 is an evolution of the original ADAPT technique, enhancing stroke thrombectomy by integrating advanced techniques for faster and more effective treatment [2] - The approach utilizes 0.088-inch intracranial access, asymmetric aspiration, and continuous dual aspiration technique (CDAT) to improve clot removal efficiency [2][5] Group 2: Clinical Data and Results - A multi-center review involved 124 ischemic stroke patients treated with ADAPT 2.0, with the M1 segment of the middle cerebral artery being the most common occlusion site (48%) [3][4] - Key findings include a median procedure time of 17 minutes, a 98% rate of full clot ingestion, and a 97% rate of final modified thrombolysis in cerebral infarction (mTICI) 2b [4][5] - The study indicated that faster treatment times correlate with higher rates of functional independence for stroke patients [3] Group 3: Zoom Stroke System Features - The Zoom Stroke System is designed for efficient clot removal in acute ischemic stroke cases, featuring various catheters and components for streamlined procedures [6][8] - All Zoom Catheters are equipped with an asymmetric TRX™ Tip, providing a 15% greater clot engagement area compared to traditional catheters [7]

Washington, D.C. 20549 _________________________________ As filed with the Securities and Exchange Commission on November 21, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 _________________________________ Beyond Air, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 3841 47-38 ...

Accessibility StatementSkip Navigation BENSALEM, Pa., Nov. 21, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Inspire Medical Systems, Inc. ("Inspire" or the "Company") (NYSE: INSP) 21% more press release views with Request a Demo Also from this source IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN INSPIRE MEDICAL SYSTEMS, INC. (INSP), CONTACT THE LAW OFFICES OF HOWARD G. SMIT ...